In this exclusive video, Lynn R. Webster, MD, from PRA Health Sciences in Salt Lake City, discusses his study from Digestive Disease Week that explored the impact of Relistor, a mu-opioid receptor agonist, on all-cause mortality in patients with opioid-induced constipation.In a retrospective analysis of 11 phase 2 and 3 randomized controlled trials, researchers found that the drug (methylnaltrexone, Salix) did reduce mortality and observed significant reductions in mortality among patients with cancer.Reference:Webster LR, et al. Abstract 8. Presented at: Digestive Disease Week; May 2-5,Read More